The actual guarantee balance provided by Anhui Conch Cement (00914) to Xi Ba Company is 122.44 million US dollars.
Anhui Conch Cement (00914) announced that its joint venture company, Xiba Company, has applied for a credit line of $40 million (approximately RMB 287.15 million) from CITIC BANK (International), with a term of 1 year. The controlling shareholder of the company and Xiba Company (PT Conch South Pacific Limited, a subsidiary of Conch Cement) and another shareholder of Xiba Company, Guangdong Rising Mineral Investment Co., Ltd. (a subsidiary of China Resources Mining) have signed a guarantee and compensation agreement with CITIC BANK (International). The company will provide an unconditional and irrevocable guarantee for the above credit in proportion to its 49% shareholding, corresponding to a guarantee amount of $19.6 million (approximately RMB 140.7 million). China Resources Mining will provide an unconditional and irrevocable guarantee for the above credit in proportion to its 51% equity, corresponding to a guarantee amount of $20.4 million (approximately RMB 146.45 million).
As of the date of this announcement, apart from the guarantees provided in this transaction, the company has provided guarantees for Xiba Company with an outstanding balance of $122.44 million (approximately RMB 878.98 million).
Related Articles

HK Stock Market Move | PA GOODDOCTOR (01833) rose nearly 9% during trading hours. Morgan Stanley is optimistic about the company's creation of a Chinese version of HMO health management model.

HK Stock Market Move | CSPC PHARMA (01093) rose more than 4% in the morning. Ethylsulfonic acid nidafeneb inhalation powder spray approved for clinical trials.

Samsung "Return of the King"? HBM4 wins back customer favor, stock price surges over 6% to a new high
HK Stock Market Move | PA GOODDOCTOR (01833) rose nearly 9% during trading hours. Morgan Stanley is optimistic about the company's creation of a Chinese version of HMO health management model.

HK Stock Market Move | CSPC PHARMA (01093) rose more than 4% in the morning. Ethylsulfonic acid nidafeneb inhalation powder spray approved for clinical trials.

Samsung "Return of the King"? HBM4 wins back customer favor, stock price surges over 6% to a new high

RECOMMEND

Hong Kong Listed Companies’ Return To A Shares Heats Up As New “H To Shenzhen A” Case Emerges
05/01/2026

What Do The Top Ten Biopharma IPOs Of 2025 Tell Us?
05/01/2026

Asia’s Stock Markets Deliver A Strong 2025: Korea Soars 76%, Japan Tops Bubble‑Era Peak, Indonesia Records Best Year In 11 Years
05/01/2026


